Publisher's Note: There is a Blood Commentary on this article in this issue.

Charles University Hospital Prague Czech Republic

Clinic 3 Hematology Oncology and Palliative Medicine University of Rostock Rostock Germany

Cologne Center of Excellence for Cellular Stress Response and Aging Related Diseases University of Cologne Cologne Germany; and

Department of Hematology University of Schleswig Holstein Kiel Germany

Department of Immunohematology and Blood Transfusion Leiden University Medical Center Leiden The Netherlands

Department of Immunology Laboratory for Medical Immunology Erasmus University Medical Center Rotterdam The Netherlands

Division of Hematology and Oncology Medical University of Innsbruck Innsbruck Austria

German CLL Study Group Department 1 of Internal Medicine and Center of Integrated Oncology Cologne Bonn University Hospital of Cologne Cologne Germany

Internal Medicine 3 University of Ulm Ulm Germany

Kantonsspital Graubünden Chur Switzerland

Oncogeriatric Unit Department of Geriatric Medicine St Marien Hospital Cologne Germany

Pharma Development Oncology F Hoffmann La Roche Ltd Basel Switzerland

Pharma Development Oncology Roche Products Ltd Welwyn United Kingdom

Royal North Shore Hospital University of Sydney Sydney Australia

Blood. 2019 Jan 31;133(5):386-388. doi: 10.1182/blood-2018-12-889113. PubMed

Zobrazit více v PubMed

Gribben JG. Chronic lymphocytic leukemia: planning for an aging population. Expert Rev Anticancer Ther. 2010;10(9):1389-1394. PubMed PMC

Barrientos JC. Management of chronic lymphocytic leukemia in the elderly. Cancer Contr. 2015;22(4 suppl):17-23. PubMed PMC

Evans SS, Clemmons AB. Obinutuzumab: A novel anti-CD20 monoclonal antibody for chronic lymphocytic leukemia. J Adv Pract Oncol. 2015;6(4):370-374. PubMed PMC

Mössner E, Brünker P, Moser S, et al. . Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood. 2010;115(22):4393-4402. PubMed PMC

Owen CJ, Stewart DA. Obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia: overview and perspective. Ther Adv Hematol. 2015;6(4):161-170. PubMed PMC

Eichhorst B, Robak T, Montserrat E, et al. ; ESMO Guidelines Committee. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v78-v84. PubMed

Wierda WG, Zelenetz AD, Gordon LI, et al. . NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2017. J Natl Compr Canc Netw. 2017;15(3):293-311. PubMed

Goede V, Fischer K, Busch R, et al. . Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014;370(12):1101-1110. PubMed

Goede V, Fischer K, Engelke A, et al. . Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study. Leukemia. 2015;29(7):1602-1604. PubMed

Goede V, Fischer K, Dyer MJS, et al. . Overall survival benefit of obinutuzumab over rituximab when combined with chlorambucil in patients with chronic lymphocytic leukemia and comorbidities: final survival analysis of the CLL11 study [abstract]. EHA Learning Center. 2018. Abstract S151.

Owen C, Christofides A, Johnson N, Lawrence T, MacDonald D, Ward C. Use of minimal residual disease assessment in the treatment of chronic lymphocytic leukemia. Leuk Lymphoma. 2017;58(12):2777-2785. PubMed

Dimier N, Delmar P, Ward C, et al. . A model for predicting effect of treatment on progression-free survival using MRD as a surrogate end point in CLL. Blood. 2018;131(9):955-962. PubMed

Wierda WG. Minimal residual disease provides treatment focus for next chronic lymphocytic leukemia advances. J Clin Oncol. 2016;34(31):3722-3723. PubMed

Böttcher S, Ritgen M, Fischer K, et al. . Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol. 2012;30(9):980-988. PubMed

Kwok M, Rawstron AC, Varghese A, et al. . Minimal residual disease is an independent predictor for 10-year survival in CLL. Blood. 2016;128(24):2770-2773. PubMed

Kovacs G, Robrecht S, Fink AM, et al. . Minimal residual disease assessment improves prediction of outcome in patients with chronic lymphocytic leukemia (CLL) who achieve partial response: comprehensive analysis of two phase III studies of the German CLL Study Group. J Clin Oncol. 2016;34(31):3758-3765. PubMed

Hallek M, Cheson BD, Catovsky D, et al. ; International Workshop on Chronic Lymphocytic Leukemia. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111(12):5446-5456. PubMed PMC

Thompson PA, Wierda WG. Eliminating minimal residual disease as a therapeutic end point: working toward cure for patients with CLL. Blood. 2016;127(3):279-286. PubMed PMC

Böttcher S, Hallek M, Ritgen M, Kneba M. The role of minimal residual disease measurements in the therapy for CLL: is it ready for prime time? Hematol Oncol Clin North Am. 2013;27(2):267-288. PubMed

Strati P, Keating MJ, O’Brien SM, et al. . Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL. Blood. 2014;123(24):3727-3732. PubMed PMC

Letestu R, Lévy V, Eclache V, et al. . Prognosis of Binet stage A chronic lymphocytic leukemia patients: the strength of routine parameters. Blood. 2010;116(22):4588-4590. PubMed

Damle RN, Wasil T, Fais F, et al. . Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999;94(6):1840-1847. PubMed

Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94(6):1848-1854. PubMed

Long-term outcomes of chemoimmunotherapy with obinutuzumab/chlorambucil in chronic lymphocytic leukemia

Patient specific real-time PCR in precision medicine - Validation of IG/TR based MRD assessment in lymphoid leukemia